INVION LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 AUD | -9.09% |
|
-9.09% | 0.00% |
| 05-08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
| 03-05 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| INVION LIMITED | Other Biotechnology & Medical Research | -9.09% | -9.09% | 0.00% | -23.08% | -64.29% | 21.3M |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- IVX Stock
- Charts Invion Limited
- Comparison Chart
